X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (100) 100
index medicus (77) 77
male (61) 61
female (60) 60
oncology (56) 56
middle aged (52) 52
aged (51) 51
adult (41) 41
lung neoplasms - drug therapy (40) 40
carcinoma, non-small-cell lung - drug therapy (36) 36
cancer (34) 34
respiratory system (33) 33
chemotherapy (30) 30
life sciences (29) 29
lung cancer (28) 28
lung neoplasms - genetics (28) 28
lung neoplasms - pathology (28) 28
lung neoplasms - mortality (25) 25
aged, 80 and over (23) 23
protein kinase inhibitors - therapeutic use (22) 22
mutation (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
prognosis (20) 20
carcinoma, non-small-cell lung - pathology (19) 19
antineoplastic agents - therapeutic use (18) 18
carcinoma, non-small-cell lung - genetics (18) 18
carcinoma, non-small-cell lung - mortality (17) 17
treatment outcome (17) 17
neoplasm staging (16) 16
[ sdv.can ] life sciences [q-bio]/cancer (15) 15
prospective studies (15) 15
research (14) 14
lung cancer, non-small cell (13) 13
patients (13) 13
adenocarcinoma (12) 12
disease-free survival (12) 12
docetaxel (12) 12
hematology, oncology and palliative medicine (12) 12
survival (12) 12
abridged index medicus (11) 11
breast-cancer (11) 11
gefitinib (11) 11
lung neoplasms - diagnosis (11) 11
open-label (11) 11
receptor, epidermal growth factor - genetics (11) 11
therapy (11) 11
cisplatin (10) 10
cisplatin - administration & dosage (10) 10
quinazolines - therapeutic use (10) 10
survival analysis (10) 10
[sdv.can]life sciences [q-bio]/cancer (9) 9
carcinoma (9) 9
lung neoplasms - therapy (9) 9
medicine, general & internal (9) 9
multivariate analysis (9) 9
mutations (9) 9
retrospective studies (9) 9
risk factors (9) 9
survival rate (9) 9
apoptosis (8) 8
biomarkers, tumor - genetics (8) 8
care and treatment (8) 8
clinical trials (8) 8
deoxycytidine - analogs & derivatives (8) 8
diagnosis (8) 8
erlotinib (8) 8
erlotinib hydrochloride (8) 8
france (8) 8
immunotherapy (8) 8
medical prognosis (8) 8
non-small cell lung cancer (8) 8
trial (8) 8
tumors (8) 8
adolescent (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
bevacizumab (7) 7
cancer therapies (7) 7
carboplatin (7) 7
cell lung-cancer (7) 7
cohort studies (7) 7
combination (7) 7
crizotinib (7) 7
deoxycytidine - administration & dosage (7) 7
disease progression (7) 7
drug therapy (7) 7
gene (7) 7
genes, p53 (7) 7
growth-factor receptor (7) 7
neoadjuvant therapy (7) 7
receptor, epidermal growth factor - antagonists & inhibitors (7) 7
research article (7) 7
surgery (7) 7
young adult (7) 7
[sdv]life sciences [q-bio] (6) 6
adenocarcinoma - genetics (6) 6
biomarkers (6) 6
biopsy (6) 6
carcinoma, non-small-cell lung - diagnosis (6) 6
carcinoma, non-small-cell lung - therapy (6) 6
cell biology (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9796, pp. 1079 - 1088
Summary Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | INTERNATIONAL-SOCIETY | GERIATRIC ASSESSMENT | UNDERREPRESENTATION | OLDER | OUTCOMES | COMBINATION | AGE | COMORBIDITY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Carboplatin - adverse effects | Carcinoma, Squamous Cell - mortality | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Paclitaxel - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Clinical trials | Chemotherapy | Radiation therapy | Cancer therapies | Adenocarcinoma | Vinblastine | Carcinoma, Non-Small-Cell Lung | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols | Lung Neoplasms | Carcinoma, Squamous Cell | Life Sciences | Deoxycytidine | Paclitaxel | Carboplatin | Cancer
Journal Article
Science, ISSN 0036-8075, 01/2018, Volume 359, Issue 6371, pp. 91 - 97
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that... 
CELL LUNG-CANCER | MELANOMA | MICROENVIRONMENT | INTESTINAL MICROBIOTA | CYCLOPHOSPHAMIDE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | GENES | RESISTANCE | ANTITUMOR IMMUNITY | NIVOLUMAB | CD4 Antigens - immunology | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Microbiome - genetics | Fecal Microbiota Transplantation | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Metagenome - genetics | Neoplasms - therapy | Animals | Receptors, CCR - immunology | Interleukin-12 - immunology | Receptors, CXCR3 - immunology | T-Lymphocytes - immunology | Mice | Gastrointestinal Microbiome - immunology | Verrucomicrobia - genetics | Verrucomicrobia - immunology | Care and treatment | Cell receptors | Microbiota (Symbiotic organisms) | Immunotherapy | Epithelial tumors | Physiological aspects | Health aspects | Methods | Apoptosis | PD-1 protein | Interleukin | Microbiomes | Transplantation | Lymphocytes T | Anticancer properties | Microbiota | Lymphocytes | Bacteria | Feces | Supplementation | Gnotobiotics | Kidneys | Melanoma | Dietary supplements | Interleukin 12 | Abundance | CXCR3 protein | Patients | CD4 antigen | Immune checkpoint | Antibiotics | Lungs | Flora | PD-L1 protein | Relative abundance | Antitumor activity | CCR9 protein | Tumors | Kidney transplantation | Cancer | Life Sciences
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1415 - 1426
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2019, Volume 37, Issue 29, pp. 2693 - 2693
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 9, pp. 992 - +
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2017, Volume 116, Issue 9, pp. 1126 - 1134
Journal Article
Circulation, ISSN 0009-7322, 05/2012, Volume 125, Issue 17, pp. 2128 - 2137
Background-The French pulmonary hypertension (PH) registry allows the survey of epidemiological trends. Isolated cases of precapillary PH have been reported in... 
Dasatinib | Chronic myeloid leukemia | Vascular complications | Adverse drug events | Pulmonary hypertension | CHRONIC MYELOGENOUS LEUKEMIA | LONG-TERM | SURVIVAL | CARDIAC & CARDIOVASCULAR SYSTEMS | MYELOPROLIFERATIVE DISORDERS | INHIBITORS IMATINIB | pulmonary hypertension | TYROSINE KINASE | CELL-GROWTH | FAILURE | NILOTINIB | CHRONIC MYELOID-LEUKEMIA | adverse drug events | vascular complications | dasatinib | chronic myeloid leukemia | PERIPHERAL VASCULAR DISEASE | Hypertension, Pulmonary - diagnosis | Follow-Up Studies | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | Hypertension, Pulmonary - chemically induced | Thiazoles - adverse effects | Antineoplastic Agents - adverse effects | Adult | Female | Registries | Antineoplastic Agents - pharmacology | Hypertension, Pulmonary - drug therapy | Drug Utilization - statistics & numerical data | Endothelin Receptor Antagonists | Bone Morphogenetic Protein Receptors, Type II - genetics | Adverse Drug Reaction Reporting Systems | Treatment Outcome | Piperazines - therapeutic use | Hypertension, Pulmonary - epidemiology | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - adverse effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Pyrimidines - adverse effects | Hydroxyurea - therapeutic use | Aged | Hemodynamics - drug effects | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Care and treatment | Dosage and administration | Drug therapy | Life Sciences | Biochemistry, Molecular Biology
Journal Article
Journal Article